US FDA Actions On Rx Drug Promos Covered New Territory Last Year

The US Food and Drug Administration’s Office of Prescription Drug Promotion issued six enforcement letters in 2020, just one more than the record low set in 2017. While citations declined they focused on some new areas, including COVID-19 claims and the placement of important safety information in emails.